Evidence map›Paper›PMID 34191227›Full record

ArticleClinical and experimental medicine2022

Associations between sarcoidosis, autoimmune diseases, and autoantibodies: a single-center retrospective study in China.

Tian-Yan Shi, Xiao-Hong Wen, Xu-Hua Shi, Juan Meng, Yue-Wu Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Autoantibodies in sarcoidosis: Innocent bystander or promising biomarker for organ involvement?Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Autoimmunity in sarcoidosis: the tip of the Iceberg.Clinical and experimental medicine · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tian-Yan ShiDepartment of Rheumatology and Clinical Immunology, Beijing Chaoyang Hospital, Capital Medical University, No. 4 Gongti South Road, Chaoyang District, Beijing, 100020, China.
Xiao-Hong WenDepartment of Rheumatology and Clinical Immunology, Beijing Chaoyang Hospital, Capital Medical University, No. 4 Gongti South Road, Chaoyang District, Beijing, 100020, China.
Xu-Hua ShiDepartment of Rheumatology and Clinical Immunology, Beijing Chaoyang Hospital, Capital Medical University, No. 4 Gongti South Road, Chaoyang District, Beijing, 100020, China.
Juan MengDepartment of Rheumatology and Clinical Immunology, Beijing Chaoyang Hospital, Capital Medical University, No. 4 Gongti South Road, Chaoyang District, Beijing, 100020, China.
Yue-Wu LuDepartment of Rheumatology and Clinical Immunology, Beijing Chaoyang Hospital, Capital Medical University, No. 4 Gongti South Road, Chaoyang District, Beijing, 100020, China. llyyww615@126.com.ORCID http://orcid.org/0000-0002-9748-0068
Capital Medical University · CN

Funding

Young Scientists Fund 81701593
6 · The paper itself

Abstract

To describe the clinical manifestations, immunological features, and risk factors in patients with sarcoidosis complicated with autoimmune diseases (ADs) as well as determine the frequency of autoantibodies and possible correlation between autoantibodies and laboratory data. Patients with pathologically confirmed sarcoidosis at Beijing Chaoyang Hospital (China) between January 2017 and October 2020 were included. Age- and sex-matched patients who visited the rheumatology outpatient clinic without systemic or ADs were included as controls. Demographic, clinical, serological, and radiological data of sarcoidosis patients were recorded and analyzed. To exclude ADs, autoantibodies, such as antinuclear antibody, extractable nuclear antigen antibodies, and anti-cyclic citrullinated peptide antibody were assessed in controls. A total of 154 sarcoidosis patients (111 females; 72.1%) with a mean ± standard deviation age of 50.7 ± 10.3 years were included. Nineteen patients (12.3%) had ADs; Hashimoto's thyroiditis (n = 6) and Sjogren's syndrome (n = 4) were common. Age, globulin, immunoglobulin G, erythrocyte sedimentation rate (ESR), and C-reactive protein were significantly different between sarcoidosis patients with and without ADs. The ESR level might be a risk factor for sarcoidosis complicated with ADs (RR = 1.053; P = 0.018). Autoantibodies were detected in 29 patients (18.8%), and the frequency was significantly higher than that in controls (18.8% vs. 3%; P = 0.001). Sarcoidosis patients were more likely to have autoantibodies despite the absence of ADs (10.4% vs. 3%; P = 0.031). Age may be a risk factor for sarcoidosis patients presenting with autoantibodies (RR = 1.077; P = 0.042). An association was identified between ADs and sarcoidosis. The inflammatory indexes, such as ESR, IgG, and CRP, were significantly different between sarcoidosis patients with and without ADs. ESR might be a risk factor for the coexistence of ADs and sarcoidosis. Sarcoidosis patients were prone to being autoantibody-positive despite the absence of ADs, and age might be a risk factor for sarcoidosis presenting with autoantibodies.

Indexed as

Autoimmune DiseasesSarcoidosisSjogren's SyndromeAdultAntibodies, AntinuclearAutoantibodiesC-Reactive ProteinFemaleHumansMiddle AgedRetrospective StudiesAntibodies, AntinuclearAutoantibodiesC-Reactive ProteinAutoantibodiesAutoimmune diseaseErythrocyte sedimentation rateRisk factorsSarcoidosis

Identifiers

PMID34191227
OpenAlexW3177141459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.